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Abstract
Activator of G protein Signaling 3 (AGS3) is a receptor-independent G protein activator that has been implicated in multiple
biological events such as brain development, neuroplasticity and addiction, cardiac function, Golgi structure/function,
macroautophagy and metabolism. However, how AGS3 is regulated is little known. We demonstrate here that AGS3
interacts with a ubiquitin specific protease USP9x, and this interaction is at least partially mediated through the C-terminal G
protein regulatory domain of AGS3. Knockdown of USP9x causes a moderate reduction in the level of AGS3. In contrast,
overexpression of either USP9x or its deubiquitinating domain UCH increases the amount of AGS3, whereas expression of
the mutant UCH domain that lacks deubiquitinating activity does not have the same effect. As previously observed in AGS3
knockdown cells, the localization of several marker proteins of the late Golgi compartments is disturbed in cells depleted of
USP9x. Taken together, our study suggests that USP9x can modulate the level of a subpopulation of AGS3, and this
modulation plays a role in regulating the structure of the late Golgi compartments. Finally, we have found that levels of
AGS3 and USP9x are co-regulated in the prefrontal cortex of rats withdrawn from repeated cocaine treatment. In
conjunction with the above data, this observation indicates a potential role of USP9X in the regulation of the AGS3 level
during cocaine-induced neuroplasticity.
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Introduction
AGS3, a member of the activator of G protein signaling (AGS)
family, was originally identified during a functional screen in
Saccharomyces cerevisiae for mammalian receptor-independent hetero-
trimeric G protein activatorproteins[1].Itis a proteinof 650 amino
acids (a.a.) and is widely expressed in multiple tissues and cell types
[2,3,4]. The N-terminal region of AGS3 contains seven tetra-
tricopeptide repeats (the TPR domain), a domain often involved in
mediating protein-protein interaction [5,6], while the C-terminal
part consists of four G protein regulatory motifs (the GPR domain),
which are known to modulate G protein signaling [5,7,8]. The TPR
and GPR domains are separated by a linker sequence in the middle.
Several early biochemical studies have shown that the GPR domain
of AGS3 preferentially binds and stabilizes the GDP-bound inactive
Ga subunits (Gai, Gat, and to a lesser extent, Gao) of
heterotrimeric G proteins, and prevents the association of GDP-
Gai with the Gbc dimer [9,10,11,12]. Thus, AGS3 acts as a
guanine dissociation inhibitor of Gai, and it inhibits the GTP-Gai
signaling pathways while stimulating Gbc-dependent pathways.
Current evidence suggests that AGS3 participates in a wide
variety of cellular events including macroautophagy [4,13], Golgi
structure/function [3], mitotic spindle orientation in cerebral
cortical progenitor cells [14], addiction-related neuroplasticity
[15,16,17,18], cardiac function and metabolism [19]. Consistent
with the involvement of AGS3 in such a diverse array of biological
processes, there are multiple pools of AGS3 within a cell. Whereas
AGS3 generally resides in the cytosol, its distribution is not
uniform [2]. Moreover, AGS3 has been shown to localize to the
cell cortex [20] as well as pre-aggresomal structures/aggresomes
[21]. A limited co-distribution between AGS3 and ER/Golgi
markers has also been reported in human intestinal HT-29 cells
[4]. Thus, one important question lies in the elucidation of
mechanisms by which a cell controls the spatial specificity of AGS3
function. The other key issue to be addressed regards the
modulation of AGS3 level. Aberrant levels of AGS3 have been
associated with drug/alcohol addiction-related behaviors
[15,16,17]. A previous report has demonstrated that the
expression of AGS3 is up-regulated in both the nucleus accumbens
core (NAC) and prefrontal cortex (PFC) of rats during late
withdrawal (3 to 8 weeks) from repeated, non-contingent,
intraperitoneal cocaine, and in the PFC following intravenous
cocaine self-administration [16]. In vivo gene targeting strategies
directed at AGS3 expression in the PFC revealed a necessary and
active role for the cocaine-induced increase in AGS3 expression in
mediating the long-term behavioral and neurochemical conse-
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NAC AGS3 expression was found to drive the reinstatement of
heroin [17] or ethanol [15] seeking in rats.
Proteins interacting with AGS3 are expected to play an
important role in regulating the positioning and/or level of
AGS3. Frmpd1, a PDZ- and FERM-domain containing protein, is
found to interact with the TPR domain of AGS3 and regulate the
AGS3 subcellular distribution by enhancing the membrane
association of AGS3 [20]. More recently, mInscutable and Gai3,
two known AGS3-binding partners, have been shown to modulate
the ability of AGS3 to distribute along the aggresomal pathway
[21]. Given that AGS3 functions in a multitude of cellular
activities associated with multiple subcellular localizations, it is
very likely that additional AGS3-interacting proteins exist to
control the function of AGS3 at specific subcellular compartments.
To gain more insight into this topic, we set forth to identify and
characterize additional AGS3-interacting proteins.
Materials and Methods
DNA constructs, RNAi and antibodies
AGS3 was cloned into the expression vector pcDNA3
(Invitrogen). Different GST fusions of AGS3 were PCR amplified
from pcDNA3AGS3, and inserted between BamHI and NotI sites
of pGEX4T-2 vector (GE healthcare). USP9x was first PCR
amplified from pDEST40-USP9x and then inserted into the
BamHI and EcoRV sites of pcDNA3 containing a C-terminal HA
tag to generate pcDNA3-USP9x-HA. After the initial cloning, the
fragment between Bsp1407I and ClaI was replaced with that of
the original construct and the remaining fragments were
sequenced. For the construction of pcDNA3-HA-UCH, the
UCH domain was PCR amplified from pcDNA3-USP9x-HA,
and inserted into BamHI and NotI sites of pcDNA3 containing an
N-terminal HA tag. pcDNA3-HA-UCH (C1571A) was generated
from pcDNA3-HA-UCH using PCR-mediated mutagenesis. The
siRNAs and shRNAs used in this study are as follows: USP9x
siRNA1 (target sequence: GACGATGTATTCTCAATCGTA;
QIAGEN), USP9x siRNA2 (target sequence: CCGCCAGATAG-
CACAACGATA; QIAGEN), USP9x shRNA2 (forward primer:
GATCCCCGGAGATGAACCTGAAAGACGACGTTATAT-
TCAAGCAGTCTTCTTTCAAGTTCATCTCCTTTTTTG;
reverse primer: AATTCAAAAAAGGAGATGAACTTGAAA-
GAAGACTGCTTGAATATAACGTCGTCTTTCAGGTTCA-
TCTCCGGG; cloned into the BamHI and EcoRI sites on pLVX-
shRNA1), USP9x shRNA3 (forward primer:GATCCCCGC-
AATCCTCCGTACACTCACAGTTATATTCAAGCATGTA-
AGTGTACTGAGGATTGCTTTTTTG;reverseprimer:AATT-
CAAAAAAGCAATCCTCAGTACACTTACATGCTTGAAT-
ATAACTGTGAGTGTACGGAGGATTGCGGG; cloned into
the BamHI and EcoRI sites on pLVX-shRNA1), AGS3 siRNA1
(target sequence: CCGGGCGCTGGAATACCACAA; QIA-
GEN), AGS3 siRNA2 (target sequence: CCGCCGAGTACTA-
CAAGAAGA; QIAGEN), and AGS3 siRNA3 (target sequence:
CTCCGAGTTCTACGAGAGGAA; QIAGEN). The shRNAs
were annealed and cloned into the BamHI and EcoRI sites of
pLVX-shRNA1 (Clontech). The antibodies used in this study
were: mouse monoclonal anti-HA (HA.11; Covance), rabbit
polyclonal anti-Gai3 (sc-262; Santa Cruz), rabbit polyclonal anti-
USP9x (Abcam), rabbit polyclonal anti-Calreticulin (Sigma),
mouse monoclonal anti-p115 (BD), mouse monoclonal anti-
bGalT1 (a gift of Dr. U. Mandel), rabbit polyclonal anti-TGN46
(Abcam), mouse monoclonal anti-Lamp1 (Hybridoma Bank),
rabbit polyclonal anti-HSP90b (Thermo Scientific), and a rabbit
polyclonal antibody raised against the GPR domain of AGS3 [13].
Cell culture and transfection
COS-7, HEK293 or HeLa cells were cultured in Advanced
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented
with 4% fetal bovine serum, 2 mM glutamine, and 2 mM
penicillin-streptomycin (Cellgro). The same medium supplement-
ed with hygromycin (200 mg/ml) was used to grow Flp-In
TM-CV1-
EGFP-AGS3 stable cells. To generate Flp-In
TM-CV1-EGFP-
AGS3, the EGFP-AGS3 fusion was cloned into pcDNA5/FRT
vector (Invitrogen), transfected into Flp-In
TM-CV1 cells (Invitro-
gen) and selected by hygromycin following manufacturer’s
instructions (Invitrogen). Tissue culture flasks or coverslips used
for growing HEK293 cells were coated with matri-gel (BD
Biosciences) overnight in a 37uC incubator before use. FuGENE
HD (Roche Applied Science) or Lipofectamine RNAiMAX
(Invitrogen) was used for transfection when needed. All siRNAs
were used at a concentration of 30 nM.
Generation and infection of lentiviral particles
HEK293T cells were maintained in DMEM medium contain-
ing 10% fetal bovine serum and 1X penicillin-streptomycin
(Cellgro) until they reached 70% confluence. Two hours before
transfection, the medium was replaced with fresh medium
preheated at 37uC. For transfection of cells grown on one 10 cm
dish, pMD2G (envelop plasmid, 2.9 mg), psPAX2 (packaging
plasmid, 5.4 mg), and either pLVX-shRNA1 (vector plasmid,
8.3 mg) or pLVX-shRNA1 containing USP9x shRNA2 or 3
(8.3 mg) were mixed in a 50 ml conical tube, followed by the
addition of 0.1X TE (1 mM Tris, 0.1 mM EDTA, pH 8.8,
242 ml), water (128 ml), and 2.5 M calcium chloride (41.5 ml). After
briefly mixing, 418 ml of 2XHBS (280 mM NaCl, 100 mM Hepes,
1.5 mM Na2HPO4, 7.11#pH#7.13) was added into the mix
dropwise under agitation by vortexing to allow the formation of
precipitation (5 min at room temperature). 830 ml of the
precipitate was then added dropwise into the cells while mixing
gently by rotating the plate. After the medium was replaced with
fresh pre-heated medium 14–16 hrs post-transfection, supernatant
was harvested 3 times every 12 hrs and kept at 4uC over the
collection period. Finally, the collected supernatants were pooled,
centrifuged for 5 min at 1500 rpm, filtered with a 0.22 mm filter,
and stored at 280uC in aliquots. To infect cells, HEK293 were
trypsinized, resuspended in the medium containing polybrene
(10 mg/ml; Sigma), and allowed to attach to the dish at a
confluence of 60–80%. The medium was then removed and kept
aside and the virus stock was added with appropriate amount of
fresh medium if needed. After letting the virus adsorb for 30–
60 min, the medium containing polybrene was added back to the
cells. Infected cells were then split and maintained in regular
medium until use.
Immunoprecipitation
Cells were lysed in ice-cold Nonidet P-40 lysis buffer (50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, and 1%
Nonidet P-40 supplemented with Complete protease inhibitors
(Roche) and 1 mM PMSF). Rat brain tissues were lysed in
homogenization buffer (20 mM Hepes, pH 7.6, 125 mM NaCl,
10% glycerol, 1 mM EDTA, 1 mM EGTA supplemented with
1% DTT). Lysates were cleared by centrifugation at maximum
speed for 10 min at 4uC. Immunoprecipitates were collected by a
brief centrifugation after incubating the supernatant with 5–
10 mg/ml primary antibody for 4 hrs followed by protein G-
Sepharose (Invitrogen) for 2 hrs at 4uC. The Sepharose beads
were washed four times in ice-cold lysis buffer, and the bound
proteins were eluted with 16SDS-PAGE sample buffer at 90uC
for 10 min.
USP9x Interacts with AGS3
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9725GST pull-down
Various regions of AGS3 were PCR amplified and cloned into
pGEX4T2 (GE Healthcare). The plasmids were utilized to
transform an Escherichia coli strain BL21 for expressing the
corresponding GST-AGS3 fusion proteins, which were purified
by using immobilized glutathione beads (Pierce) according to the
manufacturer’s instructions. HeLa cells were lysed in ice-cold
Nonidet P-40 lysis buffer. After the cell debris were cleared by
centrifugation at 4uC, the supernatant was incubated with
appropriate resin-bound GST fusion proteins for 2 hrs at 4uC
on a rocker. Following the removal the supernatant, the resin was
washed four times with ice-cold GST bind/wash buffer (Novagen)
and used for the pull-down. To examine the expression level of
various GST fusion proteins, the fusion proteins were eluted from
the beads with 16SDS-PAGE sample buffer at 90uC for 10 min.
SDS-PAGE and western blot analysis
Cells were solubilized in ice-cold RIPA lysis buffer (50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-
40, 0.5% sodium deoxycholate and 0.1% SDS, complemented
with Complete protease inhibitors (Roche) and 1 mM PMSF) and
cleared by centrifugation at 4uC. Cell lysates were quantitated
using the Non-interfering Protein Assay Kit following the
manufacturer’s instruction (G-Biosciences), and then denatured
in SDS-PAGE loading buffer. An equal amount of total protein
per sample was then loaded into each well, separated by SDS–
PAGE electrophoresis, and transferred to Immobilon 0.45 mm
polyvinylidene difluoride membranes (Millipore) using a Semi Dry
Electroblotting System (Owl). After drying, membranes were
incubated with appropriate primary antibody in a 1:1 mixture of
Odyssey blocking buffer (LI-COR) and PBST (PBS supplemented
with 0.1% Tween 20) for overnight at 4uC, washed with PBST
(three times for 10 min each), incubated with appropriate
secondary antibody (goat anti-rabbit or anti-mouse DyLight 680
or DyLight 800; Thermo Scientific) for 30 min in a 1:1 mixture of
Odyssey blocking buffer and PBST in the presence of 0.01% SDS,
washed with PBST (three times for 5 min each) followed by a final
wash with PBS for 5 min. Membranes were dried in the dark and
analyzed on an Odyssey Infrared Imaging System.
Identification of AGS3 interacting proteins by immune-
purification and mass spectroscopy
To purify AGS3 associated proteins, a mouse monoclonal anti-
GFP antibody covalently linked to magnetic microbeads (mMACS
GFP Tagged Protein Isolation Kit; Miltenyl) was used to
immunoprecipitate the EGFP-AGS3 and its associated proteins
from the Flp-In
TM-CV-1-EGFP-AGS3 stable cells under a
stringent wash condition (650 mM NaCl, 1% Igepal CA-630,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl
(pH 8.0). Flp-In
TM-CV-1 cells stably expressing EGFP alone were
included as a negative control. The immunoprecipitates were then
separated on SDS-PAGE and stained with SYPRO RUBY
(Cambrex). The putative AGS3 associated protein bands were
excised, eluted and subjected to digestion, and the resulting
peptides will be resolved by reverse-phase liquid chromatography
and detected by coupled tandem mass spectrometry (Agilent 1100
NanoFlow micro-capillary HPLC connected to a Micromass ESI-
QToF 2 mass spectrometer).
Immunofluorescence analysis and fluorescent intensity
quantification
Cells were grown on the 12-mm round glass coverslips (Warner
Instruments) and transfected with FuGENE 6 (Roche Applied
Science). After 24 hrs (for DNA transfection) or 48 hrs (for siRNA
transfection), transfected cells were fixed (in PBS containing 4%
formaldehyde, 10 min), permeabilized (in PBS containing 0.1%
saponin, 15 min), blocked (in PBS Casein Blocker (Pierce)
supplemented with 2.5% goat serum (Jackson ImmunoResearch)
and 0.1% saponin, 30 min), incubated with appropriate primary
antibody (in blocking buffer, 2 hrs), washed (in PBS, three times
for 5 min each), incubated with fluorophore-conjugated secondary
antibody (in blocking buffer, 1 hr), washed (in PBS, three times for
5 min each), incubated in PBS containing 1 mg/ml DAPI, and
washed (in PBS, two times for 3 min each). Immunostained cells
were then allowed to air dry in the dark, mounted in SlowFade
Gold antifade reagent (Invitrogen), and examined with an
Olympus IX81 microscope. AGS3 staining intensity was quanti-
fied using the ImagePro Plus 6.1 quantification software
(MediaCybernetics). After circling an area of interest around the
cell border, the area size and the AGS3 signal intensity were read
by the software. The values from 50 cells were then summed and
the average signal intensity was calculated by dividing the total
intensity of AGS3 signal by the totaled cell areas.
Analysis of cocaine-induced neuroplasticity
Adult male Sprague–Dawley rats (weighing 200–225 g; n=18)
from Harlan (Indianapolis, IN) were pair-housed in polyethylene
cages in a temperature (25uC) and humidity (71%) controlled
vivarium under a 12-hr/day light cycle (lights on: 0700 hr). Food
and water were available in the home cage ad libitum throughout
the experiment. Experimental protocols, as well as housing and
animal care, were consistent with the guidelines provided by the
National Institute of Health (NIH) Guide for Care and Use of
Laboratory Animals (NIH Publication NO. 80–23, revised 1996).
Animals were randomly assigned to either repeated cocaine or
repeated saline treatment groups. Experimental animals received
intraperitoneal (i.p.) injections of 15 mg/kg cocaine (Sigma-
Aldrich, St. Louis, MO) administered once a day for 7 consecutive
days. Control animals received equivalent volumes of saline (1 ml/
kg) for 7 consecutive days. After a withdrawal period of 21 days
following the final injection, animals were sacrificed by rapid
decapitation and the ventral prelimbic/dorsal infralimbic prefron-
tal cortex (PFC) was quickly excised bilaterally from coronal brain
slices over ice-cooled Plexiglass. Samples were immediately frozen
on dry ice and stored at 280uC prior to homogenization and
immunoblotting.
Results
USP9x is an interacting protein of AGS3
In order to search for novel AGS3-interacting proteins, we first
generated Flp-In CV-1 cells stably expressing either an EGFP
fusion of AGS3 or the EGFP alone. We then utilized magnetic
microbeads that are covalently linked to anti-GFP antibody to
immunoprecipitate the EGFP-AGS3 or EGFP (as a negative
control) and their associated proteins. As expected, the western
blot analysis of the immunoprecipitates indicated that EGFP-
AGS3, but not EGFP alone, co-immunoprecipitated with Gai3
(the bottom panel, Fig. 1A), thus validating the utilization of
EGFP-AGS3 to pull down AGS3-associated proteins. We then
conducted silver staining and found that a high molecular weight
protein highly enriched in the immunoprecipitate of the EGFP-
AGS3 stable cells compared to that of the EGFP control (the top
panel, Fig. 1A). Tandem mass spectrometry analysis identified this
protein as USP9x (Ubiquitin Specific Protease 9x). We then
generated a rabbit polyclonal antibody against the N-terminal 500
amino acids (a.a.) of USP9x and characterized the ability of this
USP9x Interacts with AGS3
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9725USP9x Interacts with AGS3
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9725antibody to detect endogenous USP9x. As shown in Fig. 1B, our
antibody recognized a band with a molecular weight similar to
that of USP9x (,290 kDa). Moreover, the intensity of this band
was greatly diminished after treating cells with either of the two
USP9x siRNAs targeting different regions of USP9x (,85%
reduction for USP9x siRNA1 and ,90% for USP9x siRNA2).
Likewise, the immunostaining intensity produced by the antibody
was significantly reduced in cells transfected with two different
USP9x siRNAs (Fig. 1C). Finally, a commercially available anti-
USP9x antibody (Abcam) detected a band of identical mobility on
SDS-PAGE and displayed the same staining pattern within cells
(data not depicted). Thus, we concluded that our antibody
recognizes endogenous USP9x in both immunoblotting and
immunofluorescence.
To confirm the interaction between endogenous AGS3 and
USP9x proteins, we performed a co-immunoprecipitation assay. A
rabbit anti-AGS3 antibody [13], but not a control rabbit IgG,
successfully co-immunoprecipitated endogenous USP9x from
HEK293 cell lysates (Fig. 1D). Similar results were obtained in
PC12, COS7 and HeLa cells (data not depicted). Given the role of
PFC AGS3 in addiction, it would be insightful to determine
whether USP9x is also associated with AGS3 in PFC. Indeed,
AGS3 co-immunoprecipitated USP9x in the rat PFC homoge-
nates (Fig. 1E). To further verify the AGS3/USP9x interaction, we
conducted a reciprocal co-immunoprecipitation using our rabbit
anti-USP9x antibody and found that this antibody can successfully
pull down AGS3 from rat PFC lysates (Fig. 1F). Taken together,
the above results demonstrate that USP9x and AGS3 can exist as a
complex in various cell lines and in the brain.
USP9x interacts with the GPR domain of AGS3
To further characterize the interaction between AGS3 and
USP9x, we carried out a GST pull-down assay to map the regions
of AGS3 interacting with USP9x. We first generated a series of
GST-fusion proteins encompassing different regions of AGS3 as
indicated in Fig. 2A. These fusions were then purified with
immobilized glutathione beads and were used to pull down USP9x
from equal amounts of HEK293 cell lysate. Fig. 2B (the lower
panel) shows that GST-GPR (a.a. 461–650), but not GST-linker
(a.a. 341–470), efficiently pulled down USP9x. Due to a low yield
of GST-TPR (a.a. 1–350) fusion (the top panel, Fig. 2B), no
conclusion can be made for the affinity of the TPR domain of
AGS3 with USP9x. These observations indicate that the AGS3/
USP9x interaction is at least partially mediated via the GPR
domain of AGS3.
The GPR domain of AGS3 is composed of four GPR motifs,
GPRI-IV, followed by the C-terminus region (CT). To further
narrow down the USP9x-interacting domain of AGS3, we
generated four additional GST fusion proteins consisting of
different regions of the GPR domain of AGS3, including GPRI-
II (a.a. 461-566), GPR III-IV (a.a. 561–624), CT (a.a. 625–650),
and GPR III-CT (a.a. 561–650). We then examined the ability of
these fusion proteins to bind USP9x from HEK293 cell lysates. As
a result, GPR III-IV and GPR III-CT fragments were able to bind
USP9x, whereas GST alone, GPR I-II and CT showed no obvious
binding to USP9x under our experimental condition (the lower
panel, Fig. 2C). This difference was not due to different expression
levels of GST fusions as shown by the Coomassie blue staining (the
top panel, Fig. 2C). Further, both GST fusions, GST-GPRI-II and
GST-GPRIII-IV, were able to interact with Gai3 (Fig. 2D). These
data suggest that the GPRIII and GPRIV motifs of AGS3 play a
major role in mediating its interaction with USP9x.
Regulation of AGS3 level by USP9x
We then asked whether the interaction of AGS3 with USP9x
has any functional impact on AGS3. One important function of
deubiquitinating enzymes is to regulate the stability of substrates
by preventing their degradation. In this regard, USP9x has been
shown to modulate the levels of several cellular proteins
[22,23,24]. Thus, we investigated whether depletion of USP9x
altered the level of AGS3. Indeed, compared to HEK293 cells
infected with a control lentivirus, cells infected with a virus
expressing either of the two USP9x shRNAs displayed a
persistently lower level of AGS3 (Fig. 3A). Although such
reduction is moderate (,20%), it is specific since these shRNAs
exerted no influence on the levels of GAPDH and b-Actin
(Fig. 3A). A similar observation was made in the human prostate
cancer cell line, Du145 (data not depicted). However, we would
like to point out that the decreased level of AGS3 is only reliably
detected after the depletion of more than 90% of endogenous
USP9x (the top panel, Fig. 3A). Presumably this indicates that low
amounts of USP9x are sufficient to prevent AGS3 degradation.
Another interpretation is that USP9x only affects a pool of AGS3.
As an alternative approach, we examined the influence of
overexpressing USP9x on the AGS3 level using immunofluores-
cence. The imaging approach was employed because the
transfection efficiency of USP9x constructs is low (ranging from
5–10%) which prevents the utilization of western blot analysis.
After confirming the specificity of our rabbit anti-AGS3 antibody
[13] in immunofluorescence with AGS3 siRNAs (Fig. 3B), we
assessed the effect of overexpressing an HA-tagged USP9x on
AGS3 staining in HEK293 cells. Relative to cells transfected with
an empty vector, cells expressing a high level of USP9x-HA
exhibited an increased staining intensity for AGS3 (Fig. 3C). To
test whether the ability of USP9x to enhance AGS3 staining
depends on its deubiquitinating activity, we repeated the
Figure 1. Identification of USP9x as an interacting protein of AGS3. (A) The SDS-PAGE and mass spectrometric analysis of the
immunoprecipitate of EGFP-AGS3 and its associated proteins from Flp-In CV1 stable cells (the top panel). The immunoprecipitate prepared from CV1
cells stably expressing the EGFP alone was included as a negative control. The nature of the doublet bands of EGFP-AGS3 is unclear but presumably
caused by protein degradation. Stably expressed EGFP-AGS3, but not EGFP alone, was also able to co-immunoprecipitate Gai3 as shown by western
blotting (the bottom panel). (B) Characterization of the rabbit anti-USP9x antibody in western blotting. The antibody was raised using the N-terminal
500 a.a. of USP9x as an antigen and the crude sera was immunopurified through a peptide column. An equal amount of cell lysates made from
HEK293 cells transfected with a non-targeting control siRNA or either of the two USP9x siRNAs (30 nM, 48 hrs) were loaded and probed with the
immunopurified antibody (1 mg/ml). GAPDH was used as a loading control and detected with a monoclonal anti-GAPDH antibody (0.2 mg/ml). (C)
Characterization of our rabbit anti-USP9x antibody in immunofluorescence. HEK293 Cells were treated with either control or one of the USP9x siRNAs
as described above, and stained with the anti-USP9x antibody (1 mg/ml). (D) Co-immunoprecipitation of USP9x with AGS3 from HEK293 cell lysates.
Lysates were incubated with an anti-AGS3 antibody (10 mg/ml) or normal rabbit IgG (10 mg/ml, a negative control) and the immunoprecipitates (IP)
were probed with either anti-AGS3 (1 mg/ml) or anti-USP9x antibody (1 mg/ml). The heterogenous band pattern of AGS3 has been previously
observed and is at least partially caused by the phosphorylation of AGS3 [13]. (E) Co-immunoprecipitation of USP9x with AGS3 from the rat brain PFC
lysate. The immunoprecipitation and western blot analysis were conducted as described in (D). (F) Co-immunoprecipitation of AGS3 with USP9x from
the rat PFC lysate. The immunoprecipitation and western blot analysis were conducted as described in (D) except that the USP9x antibody (10 mg/ml)
was used to immunoprecipitate USP9x and its associated proteins.
doi:10.1371/journal.pone.0009725.g001
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9725Figure 2. Mapping of the USP9x-interacting domain of AGS3. (A) Schematic illustration of the regions covered by the different GST-AGS3
constructs used in the GST pull-down experiments. (B) and (C) Top panels: Coomassie bluegels showed the GSTfusion proteins and their relative amounts
used in the GST pull-down. The full-length fusions are indicated by asterisks except for GST-TPR whose expression was too low to be detected. The lower
molecular weight bands are probably the products of degradation. Bottom panels: Equal amounts of HEK293 cell lysates were incubated with various GST
fusion proteins bound to glutathione beads. After wash, the GST pull-down samples were eluted from the beads and probed with anti-USP9x (1 mg/ml) in
western blot analysis. (D) The pull-down was performed as described in (C) except that the elutes were probed with an anti-Gai3 antibody (1 mg/ml).
doi:10.1371/journal.pone.0009725.g002
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9725Figure 3. Effects of depleting or overexpressing USP9x on AGS3. (A) HEK293 cells infected by the lentivirus expressing pLVX-shRNA1, USP9x-
shRNA2, or USP9x-shRNA3 were lysed and the lysates were probed with anti-AGS3 (1 mg/ml), anti-GAPDH (0.2 mg/ml), and anti-b-Actin (0.1 mg/ml)
antibodies, respectively. The values in the bar graph represent the averages from 6 independent western blot analyses quantified by Li-COR Odyssey
Infrared Imaging System (error bars: standard deviations). A representative western blot image was shown. (B) Characterization of AGS3 antibody in
immunofluorescence. Images of endogenous AGS3 in HEK293 cells transfected with a non-targeting control siRNA, or one of three different AGS3
siRNAs (siRNA1, 2 or 3; 30 nM, 48 hrs). Cells were then stained using the anti-AGS3 antibody (1 mg/ml). (C–E) Impact of overexpression of an HA-
tagged USP9x (C), or the catalytic UCH domain of USP9x (D, E), on the intensity of AGS3 staining 24 hrs after transfection. For (C) and (D), cells
overexpressing the relevant proteins are indicated by arrows, arrowheads and asterisks, and the same field is shown under both 20x and 63x
magnification in (D). Cells were co-stained with an anti-HA antibody (1:1000) and the anti-AGS3 (1 mg/ml) antibodies. For (E), the average intensity of
AGS3 staining in 50 transfected cells expressing a comparable level of HA-UCH or the catalytically inactive UCH(C/A) mutant was further quantified as
described in ‘‘Materials and Methods,’’ and the value was normalized to that of the non-transfected cells. Scale bar: 20 mm.
doi:10.1371/journal.pone.0009725.g003
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catalytic domain responsible for the deubiquitinase activity of
USP9x [25,26]. Relative to the full-length USP9x, which increased
the AGS3 staining primarily in cells expressing a high level of
transfected USP9x-HA (,30% of these cells), the UCH domain
led to enhanced AGS3 staining in almost all transfected cells
displaying a moderate-to-high level of overexpression (Fig. 3D).
The quantification analysis from 50 transfected cells indicated that
expression of the UCH domain induced a 100% increase of AGS3
staining intensity (Fig. 3E). Enhanced AGS3 staining was not
caused by the non-specific deubiquitinating activity resulted from
overexpressed UCH since the staining of Gai3 and HSP90 were
not increased under the same condition (Figs. 4A and B,
respectively). More importantly, expression of a catalytically
inactive UCH mutant, HA-UCH(C1571A) [27], failed to elicit a
similar stimulatory effect on the staining of AGS3. In contrast, the
AGS3 staining was often slightly reduced in cells expressing the
mutant (Figs. 3E and 4C), a phenomenon presumably due to a
dominant negative effect of this mutant on endogenous USP9x.
These data show that ectopic expression of USP9x at a high level
increases the staining signal of AGS3, and that this effect of USP9x
requires its deubiquitinating activity. When combined with the
above knockdown data (Fig. 3A), the most likely explanation for
the enhanced AGS3 staining is an increased amount of AGS3 in
cells expressing USP9x or UCH. However, we cannot completely
exclude the possibility that USP9x or UCH triggers a conforma-
tional change in AGS3 allowing greater antibody binding during
the process of immunostaining.
Knockdown of USP9x, as well as depletion of AGS3, leads
to dispersal of the trans-Golgi/trans-Golgi network (TGN)
We have previously reported that knockdown of AGS3 results in
a dispersed distribution of several trans-Golgi/TGN proteins
including TGN46 (a protein shuttling between TGN and plasma
membrane but enriched at TGN at the steady state) and b-GalT1
(a resident protein of trans-Golgi/TGN) [3]. This effect of AGS3 is
specific since the same treatment has no significant impact on the
subcellular localization of marker proteins of ER, early Golgi
compartments, and lysosomes [3]. Given the association between
AGS3 and USP9x, we examined how the depletion of USP9x
affects markers of the above vesicular compartments and found
that suppression of USP9x causes a very similar phenotype to that
Figure 4. Impact of overexpression of the UCH domain of USP9x (A, B), or the catalytically inactive UCH(C/A) mutant (C) on the
intensity of Gai3, HSP90 or AGS3 staining 24 hrs after transfection. Cells overexpressing the relevant proteins are indicated by arrows,
arrowheads and asterisks. Cells were co-stained with an anti-HA antibody (1:1000) (A–C) and anti-Gai3 (1 mg/ml) (A), anti-HSP90 (5 mg/ml) or anti-
AGS3 (1 mg/ml) (C) antibodies. The same field is shown under both 20x and 63x magnification. Scale bar: 20 mm.
doi:10.1371/journal.pone.0009725.g004
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depleting USP9x with either of the two shRNAs caused the
dispersal of b-GalT1 and TGN46. In contrast, both shRNAs had
little or no influence on p115 (a cis-Golgi network/cis-Golgi
marker) and Calreticulin (an ER marker) staining, respectively
(Figs. 5C and 5D). Similarly to AGS3 knockdown cells, cells
depleted of USP9x also exhibited a normal distribution of
lysosomes, as suggested by the staining of Lamp1 (Fig. 5E).
Figure 5. Influence of USP9x knockdown on the distributions of marker proteins of ER, Golgi and lysosomes. (A) HEK293 cells infected
by the lentivirus expressing pLVX-shRNA1 (non-targeting), USP9x-shRNA2, or USP9x-shRNA3 were co-stained with anti-USP9x (1 mg/ml) and anti-b-
GalT1 (1:2500) (the top panels) or co-stained with anti-b-GalT1 (1:2500) and anti-TGN46 (1:2500) (the bottom panels). (B) Percentage of cells with
condensed or dispersed TGN46 staining. The values on the bar graph represented the average from three independent experiments with more than
500 cells were counted in each experiment (error bars: standard deviation). (C–E) The same set of HEK293 cells were stained with anti-Calreticulin
(1:1000; C), p115 (1:600; D) or Lamp1 (1:3000; E), respectively. Scale bar: 20 mm.
doi:10.1371/journal.pone.0009725.g005
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modulate the level of AGS3 (or a pool of it), and that this
modulation plays a role in regulating the structure and/or function
of the late Golgi compartments.
USP9x and AGS3 are co-regulated in the rat PFC during
protracted withdrawal from repeated exposure to
cocaine
An earlier study has shown that the level of AGS3 in the PFC
region of the brain is up-regulated following prolonged cocaine
withdrawal (3–8 weeks), and this up-regulation of AGS3 is
necessary for aspects of cocaine-mediated neuroplasticity as well
as drug-seeking behavior [16]. Consistent with the previous report,
we observed an elevation (,15%) in the expression of PFC AGS3
in rats after 3 weeks of withdrawal from repeated cocaine (Fig. 6A).
Interestingly, when we tested the level of USP9x in the same PFC
samples, we found that the total expression of USP9x was also
increased (,40%) in cocaine-treated rats as compared to saline-
treated controls (Fig. 6B). This observation raises the intriguing
possibility that USP9x and AGS3 are co-regulated in the PFC
during withdrawal from repeated cocaine administration and may
provide novel insight into the regulation of cocaine-induced
changes in the levels of AGS3.
Discussion
Heterotrimeric G proteins play an essential role in mediating
the cell responses to numerous extracellular signals in various
cellular processes [28]. The binding between extracellular ligands
and the transmembrane G protein coupled receptors (GPCR)
induces a conformational change in the receptor subdomains and
promotes the exchange of GDP for GTP on the a subunit of the
heterotrimeric G protein. This nucleotide exchange leads to the
dissociation of Ga and Gbc subunits and the activation or
repression of downstream effector proteins [28]. Canonical
heterotrimeric G protein signaling is tightly regulated and requires
a GPCR. However, recent research in this area has revealed a new
class of proteins (receptor-independent G protein signaling
activators) that can activate G protein signaling without coupling
to receptors [1], and of which is AGS3 is a member. The C-
terminal part of AGS3 contains four GPR motifs that can bind to
and stabilize the GDP-bound form of specific types of Ga subunits
(Gai, Gat, and to a lesser extent, Gao), inhibit the dissociation of
GDP from Ga, and therefore block signaling events downstream
of Ga and enhance the activity of Gbc–mediated pathways
[10,11,12]. Although much has been learned about the biochem-
istry of AGS3, how AGS3 is regulated within the cell remains
largely unresolved.
In this study, we identified a new AGS3 interacting partner, the
ubiquitin specific protease USP9x, by mass spectrometry (Fig. 1A).
Co-immunoprecipitation of endogenous AGS3 and USP9x
proteins in various cell lines (i.e. HEK293, COS7, HeLa, and
PC12) and rat brain tissue (Figs. 1D–1F) indicates that the
interaction between AGS3 and USP9x is likely ubiquitous. The
GST pull-down assay (Fig. 2) further suggests that this interaction
is at least partially mediated through the GPR domain of AGS3,
although we cannot rule out a role of the TPR domain of AGS3 in
binding USP9x due to the low yield of GST-TPR fusion protein.
In spite of the existing evidence that the GPR domain of AGS3
also binds to the Gai subunit, we were unable to co-immunopre-
cipitate Gai3 using our anti-USP9x antibody and vice versa.
Moreover, overexpression of Gai3 does not influence the co-
immunoprecipitation efficiency of AGS3 and USP9x (our
unpublished data). Although these data are more consistent with
a model that USP9x and Gai3 bind to different pools of AGS3, it
remains to be determined whether USP9x can affect the
association between Gai3 and AGS3 indirectly (e.g. via the
modification of AGS3).
The observations that knockdown of USP9x decreases the
cellular level of AGS3 (Fig. 3A) and overexpression of USP9x
increases the staining intensity of AGS3 (Figs. 3C and 3D) imply
that USP9x can regulate the level of AGS3. The fact that
expression of the UCH domain alone, but not its catalytic inactive
mutant, causes an enhanced staining of AGS3 argues that the
Figure 6. Co-regulation of AGS3 and USP9x in the prefrontal
cortex (PFC) of rats after prolonged cocaine withdrawal.
Experimental rats (n=9) received once/daily i.p. injections of 15 mg/
kg cocaine for 1 week followed by 3 weeks of withdrawal. Control rats
(n=9) were injected on the same schedule with equal volumes of i.p.
saline. PFC homogenates were prepared, separated on SDS-PAGE gels
(30 mg total protein per sample), and probed with anti-AGS3 (1 mg/ml),
anti-USP9x (1 mg/ml), and anti-b-Actin (0.1 mg/ml) antibodies. Signal
intensities of AGS3 and USP9x were first normalized to that of b-Actin
for each sample, and the average normalized ratio of AGS3/Actin (A) or
USP9x/Actin (B) for the saline-treated controls was arbitrarily set to 1.
Cocaine-induced increases in AGS3 and USP9x are expressed as
multiples of the saline-treated average. Both increases were determined
to be statistically significant (AGS3 p=0.0005, USP9x p,0.0001) using a
two-tailed, equal-variance Student’s t-test.
doi:10.1371/journal.pone.0009725.g006
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for mediating the effect of USP9x on the level of AGS3 (Fig. 4).
The simplest explanation for these observations is that USP9x
influences the level of AGS3 by controlling the ubiquitination
status of AGS3. Depending on the pattern of ubiquitination,
ubiquitin modification can control protein degradation or protein-
protein interaction [29], either of which may lead to an altered
amount of AGS3 within a cell. However, our current data do not
allow us to exclude the possibility that USP9x affects the level of
AGS3 via a mechanism not involving the ubiquitination of AGS3.
Future experiments are needed to address this question.
Additionally, it is unclear why the level of AGS3 is only modestly
reduced in cells depleted of USP9x. In principle, this could
possibly be due to one or more of the following reasons. First, the
residual amount of USP9x in the knockdown cells is enough to
stabilize AGS3 to a large extent, a possibility in line with our
observation that at least 90% knockdown of USP9x is required for
the detection of a reduced AGS3 level (Fig. 3A). Second, as we
have previously discussed, AGS3 localizes to multiple subcellular
compartments. It is also possible that only a select pool of AGS3
can interact with USP9x within a cell and thus suppression of
USP9x depletes that specific pool of AGS3. Consistent with this
possibility, whereas knockdown of AGS3 results in the dispersal of
late Golgi compartments [3] as well as enhanced macroautophagy
[13], depletion of USP9x only causes the Golgi phenotype (Fig. 5)
without appreciable impact on autophagy (data not depicted).
Under this scenario, it would be worthwhile to investigate whether
USP9x modulates the level of AGS3 associated with the Golgi
membrane considering our findings that knockdown of AGS3 or
USP9x both affect the late Golgi compartments (Fig. 5).
Unfortunately, so far we have not been able to unambiguously
visualize AGS3 at the Golgi apparatus using either commercially
available antibodies or our own (data not depicted). Third, the
ability of USP9x to modulate AGS3 may be regulated (e.g. by
other proteins associated with USP9x) and thus only a fraction of
AGS3-associated USP9x is active under our experimental
condition. This model is consistent with the fact that the UCH
domain more efficiently increases AGS3 staining than full-length
USP9x (Figs. 3 and 4).
Ubiquitinating and deubiquitinating enzymes have emerged as
key players in the regulation of membrane trafficking along both
secretory and endosomal pathways in organisms ranging from
yeasts to mammals [22]. By controlling the ubiquitination status of
cargo molecules, transport machinery proteins, or the structural
components of an organelle, these enzymes can modulate
membrane trafficking via a variety of mechanisms such as
affecting the sorting of a specific cargo, impacting the level or
activity of a trafficking regulator, or modulating the assembly/
disassembly of a vesicular compartment. In this aspect, USP9x has
been previously shown to control endocytosis at the plasma
membrane through influencing the ubiquitination of Epsin, an
accessory protein of clathrin-mediated as well as clathrin-
independent internalization machinery [30,31,32]. There is also
evidence that USP9x protects the degradation of a ubiquitin ligase,
Itch, which is involved in clathrin-mediated endocytosis [33]. In
addition to its function in the endosomal pathway, Murray et al.
have suggested that USP9x associates with the E-cadherin/b-
catenin complex during its trafficking to the plasma membrane
[34]. Our study has identified a new role of USP9x in the structure
of trans-Golgi/TGN and/or the trafficking in/out of these
compartments, probably via modulating the function of AGS3.
How AGS3 and USP9x control the distributions of trans-Golgi/
TGN proteins remains an interesting question to be explored.
Knockdown of these proteins may lead to a defect in the assembly
of these compartments or an imbalanced trafficking flux in and out
of them. Gai3, a major AGS3-intercating partner, is localized to
the Golgi apparatus in many cell types [35,36,37,38,39,40] and a
Gbc signaling cascade has been shown to control the transport
between the TGN and plasma membrane [41]. Whether AGS3
exerts its action on the Golgi apparatus via affecting these Golgi-
localized G protein subunits represents an important question to
be addressed. Although we currently do not know the mechanism
by which AGS3 modulates the structure or function of the late
Golgi compartments, the observations that USP9x interacts with
AGS3 and regulates the level of AGS3 are consistent with a role of
ubiquitination/deubiquitination of AGS3 in this process. Under
this scenario, AGS3 ubiquitination may control the targeting or
level of AGS3 at the Golgi apparatus, the GDI activity of AGS3,
or the interaction of AGS3 with a yet-to-be identified protein.
Another future direction regards the observation that USP9x is co-
regulated with AGS3 in the PFC region after cocaine withdrawal ina
rat model of addiction (Fig. 6). Since up-regulation of AGS3 has been
shown to play an active role in drug/alcohol-induced neuroplasticity
[15,16,17], understanding the mechanism or mechanisms by which a
cell regulates the level of AGS3 is expected to shed light on both the
cause and the treatment of substance abuse. Although USP9x has
been implicated in the development of the nervous system [42] and
synaptic regulation [43], whether it is involved in addictive behavior
has not been documented. Our study here raises the intriguing
possibility that USP9x might contribute to cocaine-induced neuro-
plasticity via modulating the level of AGS3 in the brain.
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